Alumis Inc. (ALMS) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $24.65: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 4.14; Below-average business quality.
Alumis is a clinical-stage biopharmaceutical company developing envudeucitinib (envu), a TYK2 inhibitor, for plaque psoriasis and lupus, with an NDA submission planned for H2 2026 following positive Phase 3 ONWARD data in Q1 2026. The company has no revenue, reported a $243.3... Read more
Sell if holding. Engine safety override at $24.65: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 4.14; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 61, MACD bullish. Score 5.2/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 59d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
About Alumis Inc.
About Alumis Inc.
Alumis reported positive topline results from its Phase 3 ONWARD1 and ONWARD2 trials evaluating envudeucitinib (envu) in moderate-to-severe plaque psoriasis in January 2026, with envu meeting all primary and secondary endpoints in both studies. On average, 74% of patients achieved PASI 75 and 59% achieved sPGA 0/1 at Week 16; the company plans to submit an NDA to the FDA in the second half of 2026. At December 31, 2025, Alumis had an accumulated deficit of $901.9 million with no products approved for commercial sale.
Alumis has no revenue and funds operations through equity offerings; in March 2026, the company entered a Controlled Equity Offering agreement with Cantor Fitzgerald for up to $300.0 million. Net losses were $243.3 million in 2025 and $294.2 million in 2024. Two TYK2 inhibitors comprise the company's clinical pipeline: envu (allosteric inhibitor) in Phase 3 for plaque psoriasis and in Phase 2b for systemic lupus erythematosus — the LUMUS trial, with topline data expected in Q3 2026 — and A-005, a CNS-penetrant TYK2 inhibitor in Phase 1, targeting multiple sclerosis and neuroinflammatory diseases. Through the ACELYRIN Merger completed May 21, 2025 (a common stock transaction valued at approximately $238.1 million), the company also acquired lonigutamab, a subcutaneous monoclonal antibody targeting IGF-1R for thyroid eye disease, which remains under evaluation. Manufacturing is outsourced to contract manufacturing organizations; the filing identifies CMO performance and cGMP compliance as a supply continuity risk.
Show full overview
The company's path to profitability, per the 10-K, is dependent upon obtaining regulatory approval for and successfully commercializing envu. A second binary readout risk is the LUMUS Phase 2b trial in SLE, with topline data expected in Q3 2026; success could meaningfully expand the addressable market beyond psoriasis, while failure could limit commercial scope to a single indication. The lonigutamab TED program represents a third contingent value driver, though the filing notes lonigutamab's potential to improve on the sole currently-approved TED therapy remains unproven.
See also: Healthcare · Biotechnology
From Alumis Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-06-15Recent Developments — Alumis Inc.
Latest news
- NEWS Chardan Capital Maintains Buy on Alumis, Raises Price Target to $40 — benzinga May 19, 2026 positive
- NEWS This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday — benzinga May 15, 2026 positive
- NEWS Wells Fargo Maintains Overweight on Alumis, Raises Price Target to $51 — benzinga May 15, 2026 positive
- NEWS Guggenheim Maintains Buy on Alumis, Raises Price Target to $34 — benzinga May 15, 2026 positive
- NEWS This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday — benzinga May 15, 2026 negative
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineenvu (envudeucitinib)10-K Item 1A: 'Our ability to achieve profitability in the future is dependent upon obtaining regulatory approval for and successfully commercializing our most advanced candidate, envu'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·2 ceiling hits
Volatile — 5.4% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $24.65: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 4.14; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 61, MACD bullish. Prior stop was $22.46. Score 5.2/10, moderate confidence.
Take-profit target: $34.89 (+44.5% upside). Prior stop was $22.46. Stop-loss: $22.46.
Concentration risk — Pipeline: envu (envudeucitinib); Quality below floor (2.9 < 4.0).
Alumis Inc. trades at a P/E of N/A (forward -8.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
17 analysts cover ALMS with a consensus score of 4.4/5. Average price target: $40.
What does Alumis Inc. do?Alumis is a clinical-stage biopharmaceutical company developing envudeucitinib (envu), a TYK2 inhibitor, for plaque...
Alumis is a clinical-stage biopharmaceutical company developing envudeucitinib (envu), a TYK2 inhibitor, for plaque psoriasis and lupus, with an NDA submission planned for H2 2026 following positive Phase 3 ONWARD data in Q1 2026. The company has no revenue, reported a $243.3 million net loss in 2025, and an accumulated deficit of $901.9 million, with A-005 (CNS TYK2) and lonigutamab (TED) in earlier development.